| Literature DB >> 33194845 |
Jacques Augenstreich1, Volker Briken1.
Abstract
Mycobacterium tuberculosis (Mtb) is a very successful pathogen, strictly adapted to humans and the cause of tuberculosis. Its success is associated with its ability to inhibit host cell intrinsic immune responses by using an arsenal of virulence factors of different nature. It has evolved to synthesize a series of complex lipids which form an outer membrane and may also be released to enter host cell membranes. In addition, secreted protein effectors of Mtb are entering the host cell cytosol to interact with host cell proteins. We briefly discuss the current model, involving the ESX-1 type seven secretion system and the Mtb lipid phthiocerol dimycoserosate (PDIM), of how Mtb creates pores in the phagosomal membrane to allow Mtb proteins to access to the host cell cytosol. We provide an exhaustive list of Mtb secreted proteins that have effector functions. They modify (mostly inhibit but sometimes activate) host cell pathways such as: phagosome maturation, cell death, cytokine response, xenophagy, reactive oxygen species (ROS) response via NADPH oxidase 2 (NOX2), nitric oxide (NO) response via NO Synthase 2 (NOS2) and antigen presentation via MHC class I and class II molecules. We discuss the host cell targets for each lipid and protein effector and the importance of the Mtb effector for virulence of the bacterium.Entities:
Keywords: ESX-1; Mycobacterium tuberculosis; NOX2; cell death; cytokines; effector; lipids; phagosome maturation
Year: 2020 PMID: 33194845 PMCID: PMC7644814 DOI: 10.3389/fcimb.2020.595029
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Summary overview of Mtb protein effectors.
| PtpB | Rv0153c | ? | Phosphatase | ? | ? | Attenuated |
| HBHA | Rv0475 | ? | ? | Apoptosis (A) | No effect | |
| SodA | Rv3846 | SecA2 | Superoxide dismutase | Phagosomal Superoxides | Apoptosis (I) | Attenuated |
| Rv3654c | Rv3654c | Predicted TAT | ? | PSF | Apoptosis (I) | Attenuated |
| Rv3033 | Rv3033 | Predicted SecA1/2 SP | ? | ? | Apoptosis (I) | Attenuated |
| GroEL2/HSP65 | Rv0440 | ? | Chaperone | Mortalin | Apoptosis (I) | ? |
| Eis | Rv2416c | ? | lysine Nε-acetyltransferase activity | JNK | Apoptosis (I), Xenophagy (I), Cytokine response (I) | Not attenuated |
| MPT53/DsbE | Rv2878c | Predicted SecA1/2 | Disulfide oxidoreductase | Tak1 | Cytokine response (A) | Hypervirulent |
| PPE13 | ESX-5 | ? | NLRP3 | Cytokine response (A) | ? | |
| EchA1 | Rv0222 | ? | Probable enoyl-CoA hydratase | SHP1, TRAF6 | Cytokine response (I) | Attenuated |
| EsxA | Rv3875 | ESX-1 | ? | TLR-2, SR-B1, B2M | Cytokine response (I), Antigen presentation(I), Invasion(A), Pore formation (A) | Attenuated |
| Hip1 | Rv2224c | Predicted SecA1/2 | Esterase and Protease activity | GroEL2 (a secreted Mtb protein!) | Cytokine response (I), Apoptosis (I) | Attenuated |
| LpqN | Rv0583c | Predicted SecA1/2 | ? | CBL | Cytokine response (M) | Attenuated |
| CpnT/TNT | Rv3903c | ? | hydrolyses NAD+ | NAD+ | Necrosis (A) | Not attenuated |
| PPE2 | Rv0256c | ESX-5? | Transcriptional repressor | inos gene promotor, p67phox | NO and ROS production (I) | Attenuated |
| SapM | Rv3310 | SecA2 | Phosphatase | Phosphatidyl-inositol-3-phosphate | Phagosome maturation (I) | Attenuated |
| PknG | Rv0410c | SecA2 | Serine/Threonine kinase | Rab7L1/Rab29 | Phagosome maturation (I) | Attenuated |
| CpsA | Rv3484 | ? | ?: contains LCP and LytR domains | ?: inhibits NOX2 activation | Phagosome maturation (I) | Attenuated |
| TlyA | Rv1694 | ? | rRNA methylase, hemolysin | ? | Phagosome maturation (I) | Attenuated |
| LpdC | Rv0462 | SecA2 | Lipoamide dehydrogenase | Coronin-1 | Phagosome maturation (I) | Attenuated |
| EsxH | Rv0288 | ESX-3 | ? | HRS | Phagosome maturation (I) | Attenuated |
| PE_PGRS30 | Rv1651c | ESX-5 | ? | ? | Phagosome maturation (I) | Attenuated |
| NdkA | Rv2445c | SecA2 | GTPase Activation Protein (GAP) | Rab5, Rab7, Rac1 | Phagosome maturation (I), Apoptosis (I) | Attenuated |
| PtpA | Rv2234 | ? | Phosphatase | VPS33B, Subunit H of V-ATPase, ubiquitin, GSK3 | Phagosome maturation (I), Cytokine Response (I), Apoptosis (I) | Attenuated |
| Rv3364c | Rv3364c | ? | ? | Cathepsin G | Pyroptosis (I) | ? |
| PE_PGRS47 | Rv2741 | ESX-5 ?, Predicted SecA1/2 | ? | ? | Xenophagy (I) | Attenuated |
All listed proteins have been shown to be secreted. If data is available, the secretion mechanisms is indicated. If the secretion pathway is not yet determined, we used SignalP-5.0 to check for signal peptide prediction. The parentheses behind the host cell process indicate Activation (A), Inhibition (I) or Modulation (M). If not stated explicitly the virulence impact refers to mouse studies.
Summary overview of Mtb lipid effectors.
| PIM, LM, LAM, ManLAM | Extracellular vesicles, shedding | TLR4, TLR2-TLR1-6, MR, DC-SIGN, Dectin-2 | Cytokine response (A/I), Phagocytosis (A), phagosome maturation (I), cell death (A) | Essential, variability in acylations and LAM capping sugar moiety linked to the degree of virulence |
| TMM / TDM | Shedding | Mincle | Cytokine response (I), phagosome maturation (I) | Essential, but inability to form “cords” which is dependent on TDM attenuates the strains. |
| DAT/PAT | Extracellular vesicles, shedding | ? | Cytokine response (I), phagosome maturation (I), cell death (A) | Decreased persistence |
| PGL | Extracellular vesicles, shedding | TLR2 | Cytokine response (I) | Attenuation |
| PDIM | Shedding | ? | Cytokine responses (I) phagocytosis (A), phagosome maturation (I), phagosome escape (A), autophagy (A) apoptosis (A), necrosis (A) | Attenuation |
| SL-1 | Shedding | TLR-2 | Cytokine reponse (I), Phagosome maturation (I), autophagy (I), cell death (A) | No attenuation |
| 1-TbAd | Shedding | ? | Phagosome acidification (I) | Attenuation in human macrophages |
The parentheses behind the host cell process indicate Activation (A), Inhibition (I) or Modulation (M). If not stated explicitly the virulence impact refers to mouse studies.
Figure 1Model of the mechanism of membrane lysis by the cooperation of ESX-1 and PDIM. ESX-1 secretes EsxA and EsxB in a 1:1 heterodimer. This dimer is separated upon pH decrease and / or post-translational modifications, and free EsxA can induce pore formation. PDIM can potentiate EsxA membranolytic activity by either synergizing the pore forming activity of EsxA or by acting on the EsxA/B heterodimer complex separation.
Figure 2Host cell targets of EsxA and/or the EsxA/B complex. EsxA can antagonistically bind MHCI and TLR2, while it can bind to SR-B1 to enhance invading the lung epithelium. EsxA targets the phagosomal membrane for pore formation.
Figure 3Models of mycobacterial envelope and lipid transfer. (Left) Simplified model of the organization of the mycobacterial envelope with the main virulence lipids highlighted. (Right) Representation of the different potential mechanisms of lipid release and transfer to the host cell membrane. Lipids can be release by emission of membrane vesicles, or by shedding of the capsular layer into the phagosome lumen or due to close physical contact directly into the phagosome membrane. SL, Sulfolipids; PDIM, Phthiocerol Dimycerosates; TDM, Trehalose Dimycolates; MA, Mycolic Acid; LAM, Lipoarabinomannan.